Bioorganic & Medicinal Chemistry · 2019 · 10 citations · 41 references
MedicineMedicinal ChemistryPharmacologyAntimicrobial PharmacologyDrug DiscoverySynthetic Medicinal ChemistryAntibacterial PharmacologyAntimicrobial ToxicityAlkylation ProcessesAlkylation ReactionsAntibacterial ToxicityBacterial Biofilm ControlBacterial Biofilm EffectsBiofilm-disrupting AgentsHydrolysisProtecting Group Installation
(+)-N6-Hydroxyagelasine D, the enantiomer of the proposed structure of (−)-ageloxime D, as well as N6-hydroxyagelasine analogs were synthesized by selective N-7 alkylation of N6-[tert-butyl(dimethyl)silyloxy]-9-methyl-9H-purin-6-amine in order to install the terpenoid side chain, followed by fluoride mediated removal of the TBDMS-protecting group. N6-Hydroxyagelasine D and the analog carrying a geranylgeranyl side chain displayed profound antimicrobial activities against several pathogenic bacteria and protozoa and inhibited bacterial biofilm formation. However these compounds were also toxic towards mammalian fibroblast cells (MRC-5). The spectral data of N6-hydroxyagelasine D did not match those reported for ageloxime D before. Hence, a revised structure of ageloxime D was proposed. Basic hydrolysis of agelasine D gave (+)-N-[4-amino-6-(methylamino)pyrimidin-5-yl]-N-copalylformamide, a compound with spectral data in full agreement with those reported for (−)-ageloxime D.
41
Frederick S. Buckner, Christophe L. M. J. Verlinde, Anne Camille La Flamme et al. · Antimicrobial Agents and Chemotherapy · 1996 · 540 citations · Full text